Table 3.

Cost-effectiveness of dual-modality screening

	Lifetime costs*	QALYs*	ICER
BRCA1
Clinical Surveillance	$104,500	43.96	n/a
DM30	$109,000	44.25	$15,300
DM25	$110,300	44.26	Eliminated
Alt30	$118,000	44.37	$74,200
MRI25/Alt30	$121,700	44.39	$226,500
Alt25	$123,100	44.39‡	$978,500
BRCA2
Clinical Surveillance	$97,100	45.23	n/a
DM30	$102,100	45.52	$16,900
DM25	$103,600	45.52	Eliminated
Alt30	$115,000	45.58	$215,700
MRI25/Alt30	$118,800	45.59	$554,900
Alt25	$120,200	45.58	Eliminated

DM=digital mammography; MRI=magnetic resonance imaging; Alt=alternating DM and MRI at six-month intervals; QALY=quality-adjusted life years; ICER=incremental cost-effectiveness ratio

^*Costs (rounded to nearest hundred USD) and QALYs discounted at 3% annually

^‡Benefit <0.01, rounded to 0